WAPI's 18th Annual

Interdisciplinary CME Conference

Co-Sponsored by UW Medicine - UW CME activity number JT2101





October 10, 2020, Swedish Issaquah Medical Center 751 N.E. Blakely Drive, Issaquah

Course Fee

\$50.00

Click here to register or visit www,wapiusa.com

Course Description

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Washington School of Medicine and the Washington Association of Physicians of Indian Origin (WAPI). The University of Washington School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Washington School of Medicine designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. "Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7 MOC in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.".

To receive credit the participant must sign in and submit an evaluation.

COURSE DESCRIPTION

Personalizing HIV treatment and prevention in 2020 - Rena Patel MD .MPH

Recognize currently recommended options for initial HIV treatment regimens.

Recognize currently recommended options for HIV prevention; and Drug-drug interactions and other management considerations for a non-HIV specialist.

The current landscape for viral hepatitis and non-alcoholic fatty liver disease in the united states - Channa Jayasekara MD

Discuss the epidemiology of chronic viral hepatitis and non-alcoholic fatty liver disease in the United States, including in specific population sub-groups

Correctly interpret viral hepatitis serologies and put serologies into clinical contexts such as a) treatment indicated, b) monitor, c) at risk for disease reactivation, d) prior exposure with viral clearance. Identify current therapeutics for hepatitis B and C and Washington State's effort to eliminate hepatitis C by 2030

Describe novel therapeutic targets for hepatitis B and for nonalcoholic fatty liver disease

Testicular cancer 101 - Rohan Sharma MD

Identify current screening recommendations for testicular cancer Basic Classification and Treatment recommendations for testicular cancer

Toxicity and Survivorship Concerns for testicular cancer patients

Personalized treatment of early stage breast cancer - Swathi Namburi MD

Define the role of chemotherapy in early stage breast cancer.

Demonstrate the use of genomic predictors to personalize therapy

Describe the personalization of HER2 directed therapy in early stage
breast cancer

Women and veins - Kathy Gibson MD

Be able to differentiate between types of contraception and their risks of venous thromboembolic events.

Describe the typical presentation of a woman with symptomatic pelvic venous reflux (pelvic congestion syndrome).

Outline treatment options for patients with symptomatic varicose veins

MSK ultrasound - Atul Gupta MD

Define the place for ultrasonography within the spectrum of care for musculoskeletal pathologies.

Discuss when to consider regenerative medicine therapies for musculoskeletal pathologies.

Describe when to order an MRI versus an ultrasound for musculoskeletal pathologies.

Selecting disease-modifying anti-rheumatic drugs for rheumatoid arthritis - Amish J Dave MD

Describe the roles of the rheumatologist and primary care provider in diagnosing rheumatoid arthritis

Identify the mechanisms of action of biologic and non-biologic disease-

modifying anti- rheumatic drugs used to treat rheumatoid arthritis Compare differences in outcomes and extraarticular manifestations of rheumatoid arthritis in patients with seropositive and seronegative rheumatoid arthritis

Managing inflammatory bowel disease in the era of personalized medicine - Tim Zisman MD

Review natural history and complications of IBD and how they impact treatment approach.

Describe considerations in selecting therapy for patients with IBD Discuss strategies to optimize short- and long-term response to medication in IBD

Role of IR in treatment of progressive Parkinson's disease – Sanjiv Parikh MD

Describe treatment of Progressive Parkinson's Disease.

Describe Dopa Gel pump via dedicated Gastrojejunostomy tube

Discuss Efficacy of Dopa Gel

Targeted therapies in neurology - Leo Wang MD

Discuss Basic Pathology behind disease -Describe Therapeutic development based on pathology Analyze Cost and efficacy of treatment

Making a difference in diabetes: evaluating etiology and facing fears and falsehoods - Janet Leung MD

Compare how risk factors for diabetes in South Asian populations differ from US (with majority Caucasian ethnicity)
Discuss when to consider evaluating for T1DM in adult onset diabetes, T2DM in childhood onset diabetes, and pancreatic (Type 3c) diabetes
Outline misconceptions patient (and their communities) have about T1DM and T2DM and how that can affect management

Planning for the worst: code status, POLST, and advance care planning - Hope Wechkin, MD

Describe options for care in section B of the POLST form based on location of care.

Identify the survival-to-discharge rate of out-of-hospital cardiac arrest. Identify a tool for advance care planning for patients with dementia.

Case of HELLP syndrome - Sanjiv Parikh, MD

Describe HELLP Syndrome – a catastrophic Pregnancy complication Discuss Management of HELLP syndrome

Personal approach to healthy living - Happy Walia DDS

Discuss Approach to healthy living
Discuss role of Alcohol for healthy living

Sleep hygiene - Ashish Trivedi MD

Define good sleep hygiene

Outline current recommendation regarding the sleep duration.

WAPI's 18th Annual Interdisciplinary CME conference on 10-10- 2020

Swedish Issaquah ,751 N.E. Blakely Dr, Issaquah Co-Sponsored by UW Medicine - Program Agenda

Time Slot	CME Topic	Speaker	Speaker
7.00 - 8.00 am	Registration, Breakfast & Welcome by President	Sanjiv Parikh, MD	President, WAPI
8.00 -8.30 am	Personalizing hiv treatment and prevention in 2020	Rena Patel MD ,MPH	Assistant Professor, Division of Allergy & Infectious Diseases. UW
8.30-9am	The current landscape for viral hepatitis and non-alcoholic fatty liver disease in the United States	Channa Jayasekara MD	GI, Hepatology & Liver Transplantation - Kaiser Hepatology, Swedish Medical
9.00 am -9.30am	Testicular cancer 101	Rohan Sharma MD	Oncologist - Northwest Medical Specialties
9.30am -10am	Personalized treatment of early stage breast cancer	Swathi Namburi MD	Oncologist - Northwest Medical Specialties
10am—10.10am 10	-minute clinical vignettes: Case of HELLP syndrome – Sanjiv Parikh	MD	
10.10 am - 10.20 am	n / Break		
10.20-10.50 am	Women and Veins	Kathy Gibson MD	Vascular Surgeon
10.50 -11.20 am	MSK Ultrasound	Atul Gupta MD	Physical medicine & rehabilitation - Virginia Mason
11-20 -12.20 pm	Selecting disease-modifying anti-rheumatic drugs for rheumatoid arthritis	Amish J Dave MD	Rheumatologist Virginia Mason
12.20- 1.20 pm / Lu	nch		
1.20 - 1.50 pm	Managing inflammatory bowel disease in the era of personalized medicine	Tim Zisman MD	Tim Zisman Virginia Mason
1-50 -2.20pm	Role of IR in treatment of progressive Parkinson's disease	Sanjiv Parikh MD	Interventional Radiologist
			Swedish Medical Center
2.20- 2.30 10-minut	e clinical vignettes: Personal Approach to Healthy Living – Happy	Walia DDS	
2.30 –3.00 pm	Targeted Therapies in Neurology	Leo Wang MD	Associate professor of Neurology UW
3.00 -3.10 / Break			
3.10-3.20 pm Rapid	Fire 10-minute clinical vignettes: Sleep Hygiene – Ashish Trivedi M	1D	
3.20 -3.50 pm	Making a difference in diabetes: evaluating etiology and facing fears and falsehoods	Janet Leung MD	Endocrinologist Virginia Mason
3.50 -4.20 pm	Planning for the worst: code status, POLST, and advance care planning	Hope Wechkin, MD	Medical Director Evergreen Health Hospice and Palliative Care